Table 1 Demographic and clinical characteristics for cervical cancer patients diagnosed with and without liver metastasis
Subject characteristics | No. of cervical cancer patients (2010–2015) | χ2 | P-value | |
|---|---|---|---|---|
With LM (N = 431, 2.32%) | Without LM (N = 18,127, 97.68%) | |||
Age in years |  |  | 68.154 | < 0.001 |
 18–40 | 55 (12.8%) | 5320 (28%) |  |  |
 41–64 | 244 (56.6%) | 10,125 (53.3%) |  |  |
  ≥ 65 | 132 (30.6%) | 3544 (18.7%) |  |  |
Year of diagnosis | Â | Â | 3.63 | 0.163 |
 2010–2011 | 124 (28.8%) | 6292 (33.1%) |  |  |
 2012–2013 | 149 (32.6%) | 6175 (32.5%) |  |  |
 2014–2015 | 158 (36.7%) | 6522 (34.35) |  |  |
Race | Â | Â | 17.867 | 0.001 |
 White | 296 (68.7%) | 14,170 (74.6%) |  |  |
 Black | 88 (20.4%) | 2620 (13.8%) |  |  |
 Others | 46 (10.7%) | 2005 (10.6%) |  |  |
 Unknown | 1 (0.2%) | 194 (1.0%) |  |  |
Marital status | Â | Â | 1.183 | 0.553 |
 Married | 263 (61.0%) | 12,062 (63.5%) |  |  |
 Unmarried | 138 (32.0%) | 5733 (30.2%) |  |  |
 Unknown | 30 (7.0%) | 1194 (6.3%) |  |  |
Insurance | Â | Â | 6.827 | 0.033 |
 Insured | 380 (88.2%) | 17,242 (90.8%) |  |  |
 Uninsured | 41 (9.5%) | 1220 (6.4%) |  |  |
 Unknown | 10 (2.3%) | 527 (2.8%) |  |  |
Primary Site |  |  | 20.689 | < 0.001 |
 Endocervix | 48 (11.1%) | 3590 (18.9%) |  |  |
 Exocervix | 3 (0.7%) | 341 (1.8%) |  |  |
 Overlapping lesion of cervix | 7 (1.6%) | 304 (1.6%) |  |  |
 Cervix uteri, unspecified | 373 (86.5%) | 14,754 (77.7%) |  |  |
AJCC stage | ||||
 T stage |  |  | 169.341 | < 0.001 |
  T1 | 59 (13.7%) | 10,397 (54.8%) |  |  |
  T2 | 73 (16.9%) | 4170 (22.0%) |  |  |
  T3 | 144 (33.4%) | 2911 (15.3%) |  |  |
  T4 | 61 (14.2%) | 671 (3.5%) |  |  |
  Unknown | 94 (21.8%) | 840 (4.4%) |  |  |
 N stage |  |  | 468.148 | < 0.001 |
  N0 | 124 (28.8%) | 13,554 (71.4%) |  |  |
  N1 | 218 (50.6%) | 4622 (24.3%) |  |  |
  Unknown | 89 (20.6%) | 813 (4.3%) |  |  |
Grade |  |  | 615.394 | < 0.001 |
 I | 4 (0.9%) | 2141 (11.3%) |  |  |
 II | 54 (12.5%) | 5940 (31.3%) |  |  |
 III | 175 (40.6%) | 5353 (28.2%) |  |  |
 IV | 28 (6.5%) | 417 (2.2%) |  |  |
 Unknown | 170 (39.4%) | 5138 (27.1%) |  |  |
Histology |  |  | 132.849 | < 0.001 |
 SCC | 207 (48.0%) | 12,429 (65.5%) |  |  |
 AC | 97 (22.5%) | 4366 (23.05) |  |  |
 Others | 127 (29.5%) | 2194 (11.6%) |  |  |
Tumor size |  |  | 152.343 | < 0.001 |
  ≤ 2 cm | 12 (2.8%) | 4168 (21.9%) |  |  |
  > 2, ≤4 cm | 31 (7.2%) | 3031 (16.0%) |  |  |
  > 4 cm | 140 (39.4%) | 5861 (30.9%) |  |  |
 Unknown | 218 (50.6%) | 5929 (31.2%) |  |  |
Surgery primary site |  |  | 365.563 | < 0.001 |
 Yes | 386 (89.6%) | 8243 (43.4%) |  |  |
 No | 45 (10.4%) | 10,712 (56.4%) |  |  |
 Unknown | 0 (0.0%) | 34 (0.2%) |  |  |
Lung Met |  |  | 2397.509 | < 0.001 |
 No | 204 (47.3%) | 18,331 (96.5%) |  |  |
 Yes | 204 (47.3%) | 622 (3.3%) |  |  |
 Unknown | 23 (5.3%) | 36 (0.2%) |  |  |
Bone Met |  |  | 1723.957 | < 0.001 |
 No | 286 (66.4%) | 18,634 (98.1%) |  |  |
 Yes | 128 (29.7%) | 330 (1.7%) |  |  |
 Unknown | 17 (3.9%) | 25 (0.1%) |  |  |
Brain Met |  |  | 685.061 | < 0.001 |
 No | 391 (90.7%) | 18,911 (99.6%) |  |  |
 Yes | 18 (4.2%) | 61 (0.3%) |  |  |
 Unknown | 22 (5.1%) | 17 (0.1%) |  |  |
Radiotherapy | Â | Â | 8.924 | 0.003 |
 Yes | 206 (47.8%) | 10,451 (55.0%) |  |  |
 No/ Unknown | 225 (52.2%) | 8538 (45.0%) |  |  |
Chemotherapy |  |  | 22.572 | < 0.001 |
 Yes | 263 (61.0%) | 9390 (49.4%) |  |  |
 No/Unknown | 168 (39.0%) | 9599 (50.6%) |  |  |
Status (%) |  |  | 773.048 | < 0.001 |
 Alive | 37 (8.6%) | 13,467 (70.9%) |  |  |
 Dead | 394 (91.4%) | 5522 (29.1) |  |  |
 Median survival time(IQR) | 5 (2–11) | 29 (14–52) |  |  |